Literature DB >> 2015875

Splenic irradiation in chronic lymphocytic leukemia.

T Chisesi1, G Capnist, S Dal Fior.   

Abstract

52 patients with CLL, presenting primarily with splenomegaly, stage II-IV according to the Rai stage system, were treated with a regime of low-dose splenic irradiation (SI) between January, 1979 and December 1987. The treatment modality consisted of 1 Gy, from 1 to 10 doses, given at weekly intervals. The median given dose was 700 cGy (100-1000). CHR occurred in 23/52 (44%), PR in 20/52 (38%) and no response (NR) in 9/52 (17%) of the patients. The median duration of remission was 9 months (range 3-24), 15 and 7 months for patients achieving CHR and PR, respectively. At relapse, 14 patients received a second course of SI by the same modalities: 2 of them obtained a second CHR, 9 a PR and 3 NR. The median duration of remission was 4 months. In conclusion, SI represents a suitable therapy for CLL patients presenting primarily with splenomegaly. The low rate of response and the short remission duration after the second treatment suggest that SI should be combined either with splenectomy or with other therapeutic approaches.

Entities:  

Mesh:

Year:  1991        PMID: 2015875     DOI: 10.1111/j.1600-0609.1991.tb00541.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

Review 1.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 2.  Personalized medicine in CLL: current status and future perspectives.

Authors:  Uri Rozovski; Inbal Hazan-Halevy; Michael J Keating; Zeev Estrov
Journal:  Cancer Lett       Date:  2013-07-20       Impact factor: 8.679

Review 3.  Chronic lymphocytic leukemia.

Authors:  Leslie Andritsos; Hanna Khoury
Journal:  Curr Treat Options Oncol       Date:  2002-06

4.  Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation.

Authors:  Andrea Riccardo Filippi; Pierfrancesco Franco; Marco Galliano; Umberto Ricardi
Journal:  Radiat Oncol       Date:  2006-09-06       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.